Serum Proteome Profiling Identifies Novel and Powerful Markers of Cystic Fibrosis Liver Disease

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Rath, Timo ^a   Hage, Lisa ^a   Kügler, Marion ^a   Menendez Menendez, Katrin ^a   Zachoval, Reinhart ^b   Naehrlich, Lutz ^c   Schulz, Richard ^a   Roderfeld, Martin ^a   Roeb, Elke ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ADAMTS1 PROTEIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; ENDOGLIN; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PENTRAXIN 3; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA1; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS ASSOCIATED LIVER DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; ELASTOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER STIFFNESS; MALE; NON INVASIVE MEASUREMENT; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSIENT ELASTOGRAPHY; ULTRASOUND SCANNER; UPREGULATION; VALIDATION PROCESS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; PROTEOMICS; TISSUE INHIBITOR OF METALLOPROTEINASES; YOUNG ADULT;

EID: 84875015757     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058955     Document Type: Article

References (64)

1. Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D, et al. (2002) Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology 36: 1374-1382.
2. Lindblad A, Glaumann H, Strandvik B, (1999) Natural history of liver disease in cystic fibrosis. Hepatology 30: 1151-1158.
3. Moyer K, Balistreri W, (2009) Hepatobiliary disease in patients with cystic fibrosis. Curr Opin Gastroenterol 25: 272-278.
4. Debray D, Kelly D, Houwen R, Strandvik B, Colombo C, (2011) Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 10Suppl 2: S29-36.
5. Sokol RJ, Durie PR, (1999) Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 28Suppl 1: S1-13.
6. Bedossa P, Dargere D, Paradis V, (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 38: 1449-1457.
7. Colloredo G, Guido M, Sonzogni A, Leandro G, (2003) Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 39: 239-244.
8. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, et al. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614-2618.
9. Bravo AA, Sheth SG, Chopra S, (2001) Liver biopsy. N Engl J Med 344: 495-500.
10. Cadranel JF, Rufat P, Degos F, (2000) Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 32: 477-481.
11. Castera L, Negre I, Samii K, Buffet C, (1999) Pain experienced during percutaneous liver biopsy. Hepatology 30: 1529-1530.
12. Malbrunot-Wagner AC, Bridoux L, Nousbaum JB, Riou C, Dirou A, et al. (2011) Transient elastography and portal hypertension in pediatric patients with cystic fibrosis Transient elastography and cystic fibrosis. J Cyst Fibros.
13. Witters P, De Boeck K, Dupont L, Proesmans M, Vermeulen F, et al. (2009) Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease. J Cyst Fibros 8: 392-399.
14. Rath T, Menendez KM, Kugler M, Hage L, Wenzel C, et al. (2012) TIMP-1/-2 and transient elastography allow non invasive diagnosis of cystic fibrosis associated liver disease. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 44: 780-787.
15. Gressner AM, Gao CF, Gressner OA, (2009) Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J Gastroenterol 15: 2433-2440.
16. Rath T, Roderfeld M, Guler C, Wenzel C, Graf J, et al. (2011) YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scandinavian Journal of Gastroenterology 46: 1369-1380.
17. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, et al. (2007) Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 176: 957-969.
18. Kerem E, Conway S, Elborn S, Heijerman H, (2005) Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 4: 7-26.
19. Bland JM, Altman DG, (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307-310.
20. Menten R, Leonard A, Clapuyt P, Vincke P, Nicolae AC, et al. (2010) Transient elastography in patients with cystic fibrosis. Pediatric radiology 40: 1231-1235.
21. Karlas T, Neuschulz M, Oltmanns A, Guttler A, Petroff D, et al. (2012) Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. PloS one 7: e42139.
22. Ramsey BW, Boat TF, (1994) Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference. The Journal of pediatrics 124: 177-192.
23. Kerem E, Conway S, Elborn S, Heijerman H, (2005) Standards of care for patients with cystic fibrosis: a European consensus. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 4: 7-26.
24. Gault R, (2002) Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. Pediatric physical therapy: the official publication of the Section on Pediatrics of the American Physical Therapy Association 14: 157-158.
25. Baranova A, Lal P, Birerdinc A, Younossi ZM, (2011) Non-invasive markers for hepatic fibrosis. BMC gastroenterology 11: 91.
26. Castera L, (2011) Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best practice & research Clinical gastroenterology 25: 291-303.
27. Colombo C, Russo MC, Zazzeron L, Romano G, (2006) Liver disease in cystic fibrosis. J Pediatr Gastroenterol Nutr 43Suppl 1: S49-55.
28. Herrmann U, Dockter G, Lammert F, (2010) Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol 24: 585-592.
29. Breton E, Bridoux-Henno L, Guyader D, Danielou H, Jouan H, et al. (2009) [Value of transient elastography in noninvasive assessment in children's hepatic fibrosis]. Arch Pediatr 16: 1005-1010.
30. Schuppan D, Afdhal NH, (2008) Liver cirrhosis. Lancet 371: 838-851.
31. Bissell DM, Roulot D, George J, (2001) Transforming growth factor beta and the liver. Hepatology 34: 859-867.
32. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S, (2002) Roles of TGF-beta in hepatic fibrosis. Frontiers in bioscience: a journal and virtual library 7: d793-807.
33. Rodgarkia-Dara C, Vejda S, Erlach N, Losert A, Bursch W, et al. (2006) The activin axis in liver biology and disease. Mutation research 613: 123-137.
34. Zhang LP, Takahara T, Yata Y, Furui K, Jin B, et al. (1999) Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. Journal of hepatology 31: 703-711.
35. Garcia-Alvarez M, Berenguer J, Guzman-Fulgencio M, Micheloud D, Catalan P, et al. (2011) High plasma fractalkine (CX3CL1) levels are associated with severe liver disease in HIV/HCV co-infected patients with HCV genotype 1. Cytokine 54: 244-248.
36. Hemmann S, Graf J, Roderfeld M, Roeb E, (2007) Expression of MMPs and TIMPs in liver fibrosis- a systematic review with special emphasis on anti-fibrotic strategies. Journal of hepatology 46: 955-975.
37. Roeb E, Purucker E, Breuer B, Nguyen H, Heinrich PC, et al. (1997) TIMP expression in toxic and cholestatic liver injury in rat. J Hepatol 27: 535-544.
38. Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJ, (1996) Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110: 821-831.
39. Yata Y, Takahara T, Furui K, Zhang LP, Jin B, et al. (1999) Spatial distribution of tissue inhibitor of metalloproteinase-1 mRNA in chronic liver disease. J Hepatol 30: 425-432.
40. Lichtinghagen R, Bahr MJ, Wehmeier M, Michels D, Haberkorn CI, et al. (2003) Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci (Lond) 105: 373-382.
41. Boker KH, Pehle B, Steinmetz C, Breitenstein K, Bahr M, et al. (2000) Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis. Hepatogastroenterology 47: 812-819.
42. Nadler EP, Li X, Onyedika E, Greco MA, (2010) Differential expression of hepatic fibrosis mediators in sick and spontaneously recovered mice with experimental biliary atresia. The Journal of surgical research 159: 611-617.
43. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, et al. (2004) Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127: 1704-1713.
44. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, et al. (2004) Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. Journal of hepatology 41: 935-942.
45. Rodriguez-Barbero A, Obreo J, Eleno N, Rodriguez-Pena A, Duwel A, et al. (2001) Endoglin expression in human and rat mesangial cells and its upregulation by TGF-beta1. Biochemical and biophysical research communications 282: 142-147.
46. Meurer SK, Tihaa L, Lahme B, Gressner AM, Weiskirchen R, (2005) Identification of endoglin in rat hepatic stellate cells: new insights into transforming growth factor beta receptor signaling. The Journal of biological chemistry 280: 3078-3087.
47. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, et al. (2002) Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis and rheumatism 46: 1857-1865.
48. Chen K, Mehta JL, Li D, Joseph L, Joseph J, (2004) Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circulation research 95: 1167-1173.
49. Meurer SK, Tihaa L, Borkham-Kamphorst E, Weiskirchen R, (2011) Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. Cellular signalling 23: 683-699.
50. Yagmur E, Rizk M, Stanzel S, Hellerbrand C, Lammert F, et al. (2007) Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma. European journal of gastroenterology & hepatology 19: 755-761.
51. Clemente M, Nunez O, Lorente R, Rincon D, Matilla A, et al. (2006) Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis. Journal of viral hepatitis 13: 625-632.
52. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, et al. (1989) Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443.
53. Moriyama M, Matsumura H, Watanabe A, Oshiro S, Aoki H, et al. (2005) Evaluation of serum concentrations of human hepatocyte growth factor during interferon therapy for chronic hepatitis C. Intervirology. 48: 223-229.
54. Yamagami H, Moriyama M, Tanaka N, Arakawa Y, (2001) Detection of serum and intrahepatic human hepatocyte growth factor in patients with type C liver diseases. Intervirology 44: 36-42.
55. Shiota G, Okano J, Kawasaki H, Kawamoto T, Nakamura T, (1995) Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology 21: 106-112.
56. Tsubouchi H, Kawakami S, Hirono S, Miyazaki H, Kimoto M, et al. (1992) Prediction of outcome in fulminant hepatic failure by serum human hepatocyte growth factor. Lancet 340: 307.
57. Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, et al. (2011) Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 30: 761-766.
58. Bottazzi B, Garlanda C, Salvatori G, Jeannin P, Manfredi A, et al. (2006) Pentraxins as a key component of innate immunity. Current opinion in immunology 18: 10-15.
59. Garlanda C, Bottazzi B, Bastone A, Mantovani A, (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annual review of immunology 23: 337-366.
60. Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, et al. (2001) PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis and rheumatism 44: 2841-2850.
61. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, et al. (2000) PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102: 636-641.
62. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, et al. (2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110: 2349-2354.
63. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, et al. (2001) Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. The Journal of infectious diseases 184: 355-358.
64. Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, et al. (2008) Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC gastroenterology 8: 53.